Stay in touch
Prime news from our network.
#read
Saxony develops pioneering cancer medicine with AI and genetics
A new generation of living drugs with the potential to fundamentally change cancer therapy is being developed in Dresden and Leipzig. In the Saxocell research alliance, scientists are using genetic engineering and artificial intelligence (AI) to develop personalised CAR-T cell therapies.
04/02/2025
This involves genetically modifying the patient's own immune cells so that they specifically combat tumour cells. The Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig plays a key role in this process. With its automated manufacturing processes, it is one of the largest academic production centres for cell preparations in Europe. Clinical studies on the effectiveness of the novel therapy against cancer and autoimmune diseases are already underway. Saxocell, one of the country's future clusters, recently received 15 million euros for a second funding phase until 2027 with the aim of drastically reducing the costs of CAR-T therapies and making the treatment accessible to a broader group of patients. In the long term, the cell preparations „Made in Saxony“ could not only help cancer patients, but also people with cardiovascular and neurodegenerative diseases.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.